Need for Aligning the Definition and Reporting of Cytokine Release Syndrome (CRS) in Immuno-Oncology Clinical Trials [PDF]
As cancer immunotherapies continue to expand across all areas of oncology, it is imperative to establish a standardized approach for defining and capturing clinically important toxicities, such as cytokine release syndrome (CRS). In this paper, we provide considerations for categorizing the variety of adverse events that may accompany CRS and for ...
Elad Sharon, Jeff Allen, Mark Stewart
exaly +5 more sources
Management of Cytokine Release Syndrome (CRS) and HLH [PDF]
AbstractCytokine release syndrome (CRS) is caused by a rapid and mild to massive release of cytokines from immune cells involved in immune reactions, particularly after immunotherapy. The frequency and severity of CRS after CAR-T cell therapy varies between products (any grade: 37–93%, G3/4: 1–23%) (Neelapu et al. 2017; Schuster et al.
Ulrich Jaeger
exaly +3 more sources
Severe Cases of Local Cytokine Release Syndrome (CRS); Craniocervical Edema Soon After Chimeric Antigen T-Cell (CAR-T) Therapy [PDF]
Craniocervical edema appears soon after chimeric antigen receptor T-cell (CAR-T) therapy in some cases. This phenomenon is often observed right after systemic cytokine release syndrome (CRS), and it is called local CRS (L-CRS).
Akifumi Takaori-Kondo +2 more
exaly +4 more sources
Can We Use Interleukin-6 (IL-6) Blockade for Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)? [PDF]
Chunlan Zhang, Yufei Xiang
exaly +2 more sources
Related searches:
Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab Administration
Blood, 2023Introduction: Teclistamab is a T-cell redirecting bispecific antibody that targets both CD3 on the T-cell surface and B-cell maturation antigen (BCMA) expressed on myeloma cells. Teclistamab gained accelerated approval for RRMM patients that had previously been treated with 4 prior lines of therapy including a PI, IMID and a CD38 ...
Ellen Marin +9 more
openaire +1 more source
Extracorporeal cytokine adsorption for treating severe refractory cytokine release syndrome (CRS)
Bone Marrow Transplantation, 2020International ...
Wallet, Florent +7 more
openaire +3 more sources
Overview on the Use of IL-6 Agents in the Treatment of Patients With Cytokine Release Syndrome (CRS) and Pneumonitis Related to COVID-19 Disease [PDF]
A novel coronavirus pneumonia (COVID-19) has caused significant life loss and healthcare burden globally. COVID-19 is known to cause a cytokine release syndrome (CRS) like response, and interleukin-6 (IL-6) is one of the cytokines involved. Clinicians are using IL-6 inhibitors to CRS, and researchers are investigating the use of IL-6 inhibitors, namely
Christina Price, Zeyun Zhou
exaly +3 more sources
Background Cytokine Release Syndrome (CRS) is a well-recognized toxicity that occurs with high frequency following treatments such as T-cell engaging antibodies, Chimeric Antigen Receptor (CAR) T cells and other T-cell boosting immunotherapies.
Emma Searle +5 more
openaire +1 more source
Abstract Background: Cytokine release syndrome (CRS) in the setting of CAR T cell therapy manifests as a wide constellation of symptoms with multi-organ involvement. CRS can vary from a mild, self-limited course to a life-threatening systemic inflammatory response which, in severe cases, may be associated with manifestations similar to ...
Crystal Mackall +2 more
exaly +2 more sources
Towards a safer CD19 CART therapy with reduced risk of cytokine release syndrome (CRS).
Journal of Clinical Oncology, 20163049Background: Despite remarkable clinical success, adoptive T-cell therapy (ACT) with anti-CD19 chimeric antigen rector (CAR) T cells is hindered by both pro-inflammatory and immuno-suppressive a...
Lucas H. Horan, Cheng Liu
openaire +1 more source

